Firalis S.A. is proud to announce its participation in the national effort to combat COVID-19
with the development of "EasyCOV" saliva test
Huningue, France, 18th June 2020
As part of the development of the EasyCOV saliva test, Firalis is the productor of the test at its facilities in Huningue, as well as for the CE-marking process necessary for its clinical use. This project is a collaboration led by Sys2diag Laboratory, the Skillcell company and the Vogo, a technology startup.
EasyCov is a non-invasive diagnostic test being used in the French medical institutions, government and companies.
The purpose of this test, which can be easily used in the field by the medical profession, is to identify people with Covid-19 and thus enable better management of the health crisis. This, unlike other tests that require several hours of laboratory treatment and require extensive equipment and reagents.
"Easycov is very easy to use: take a little saliva under the tongue using a pasteur pipette which is then inserted into a tube containing reagents, mixed and heated to 65°C. The result, in the form of a colorimetric revelation, is easily interpretable."
Alexandra Prieux, President of SkillCell.
Firalis has just signed an order for 100,000 tests last May and continues to adapt its large-scale production to provide several hundred thousand tests per week. A way to highlight its know-how in the production of diagnostic kits.
“It was our moral duty, as a French biotechnology company, to respond to the development of a rapid and effective test in order to participate in the collective effort in the fight against the current pandemic.”
Hüseyin Firat, CEO of Firalis S.A.
Illustration of the COVID-19 virus – Photo credit: Passeport santé
About FIRALIS S.A.
Firalis S.A. is a biotechnology company developing diagnostic products based on the discovery, clinical validation and regulatory qualification of biomarkers for precision medicine, to improve the diagnosis of various diseases and therapeutic decisions. Firalis is already on the market with other in vitro diagnostic tests, especially for heart failure, and the world leader through its subsidiary Amoneta Diagnostics in the ongoing development of an innovative pipeline of tests for early diagnosis of Alzheimer’s disease.
Sources : Les Echos : EasyCov, un test salivaire de dépistage rapide du Covid-19
Press contact: firstname.lastname@example.org - FIRALIS - +33 (0) 389 91 13 20